Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer
European Urology Focus · 2026-06 · 12 (3) · 572-575
DOI: 10.1016/j.euf.2026.03.002 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift European Urology Focus, 2026-06. Verfasst von Mahtab Hamidikia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Androgen Antagonists, Androgen Receptor Antagonists, Phenylthiohydantoin, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Continuous treatment with an androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in low-volume metastatic castration-sensitive prostate cancer (mCSPC) may lead to overtreatment, resulting in increased toxicity and higher costs. Evidence to guide a shorter duration of ARPI therapy is currently lacking. The Apa/Enza-short trial evaluates whether a 12-mo course of apalutamide or enzalutamide is noninferior to continuous treatment in low-volume mCSPC. This randomized, open-label, noninferiority study enrolls 400 patients across Dutch hospitals. After 12 mo of ADT + ARPI, eligible patients are randomized to continue or discontinue ARPI treatment, with reinitiation permitted upon prostate-specific antigen (PSA) increase. The primary end point is clinical progression-free survival (cPFS). If noninferiority is demonstrated, this strategy could maintain efficacy while reducing treatment-related toxicity and health care costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: n.beije@erasmusmc.nl.
Zitieren
APA
Hamidikia, M., van Dijk, T. C., Martens, J. W. M., Isebia, K. T., de Wit, R., & Beije, N. (2026). Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer. European Urology Focus, 12(3), 572-575. https://doi.org/10.1016/j.euf.2026.03.002
Vancouver
Hamidikia M, van Dijk TC, Martens JWM, Isebia KT, de Wit R, Beije N. Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer. European Urology Focus. 2026;12(3):572-575. doi:10.1016/j.euf.2026.03.002
BibTeX
@article{Hamidikia2026,
author = {Hamidikia, Mahtab and van Dijk, Tanja C and Martens, John W M and Isebia, Khrystany T and de Wit, Ronald and Beije, Nick},
title = {Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {3},
pages = {572--575},
doi = {10.1016/j.euf.2026.03.002}
}
EUVIMED